激素抵抗型前列腺癌新的治疗方法
New Treatment Methed for Hormone Refractory Prostate Cancer
摘要
激素抵抗型前列腺癌是临床治疗上的重点和难点,目前的治疗方法包括化疗、放疗、核素内照射以及双磷酸盐等疗效均不满意,文章综述了近年来激素抵抗型前列腺癌新的治疗方法。
出处
《肿瘤学杂志》
CAS
2008年第3期232-235,共4页
Journal of Chinese Oncology
参考文献27
-
1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007 [J]. CA Cancer J Clin, 2007, 57(1):43-66.
-
2Alan S, Martin G, Antonio H, et al. Mechanism of the development of androgen independence in prostate cancer[J]. World J Urol, 2005, 23(1):1-9.
-
3Heidenreich A,Von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer[J]. Eur Urol, 2001, 39(2): 121-130.
-
4Steinberg CN, Whelan P, Hetherington J, et al. Phase Ⅲ trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone refractory prostate cancer[J]. Oncology, 2005, 68(1): 229.
-
5Smaletz O, Galsky M, Scher HI, et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration [J]. Ann Oncol, 2003, 14 (10): 1518-1524.
-
6Hussain A, Dipaola RS, Baron AD, et al. A phase Ⅱ a trial of weekly EP0906 in patients with hormone-refractory prostate cancer (HPRC)[J]. Proc Am Soc Clin Oncol, 2004, 23:396-399.
-
7Hussain M,Faulkner J, Vaishampayan U, et al. Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (SO111)[J]. Proc Am Soc Clin Oncol, 2004, 23:383.
-
8Kelly WK, Galsky MD, Small E J, et al. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): updated results[J]. Proc Am Soc Clin Oncol, 2004, 23:383.
-
9Rosenberg JE,Galsky MD, Rohs NC, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxanebased therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy[J].Cancer,2006,106(1): 58-62.
-
10Beinart G, Rini BI, Weinberg V, et al. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer [J]. Clin Prostate Cancer, 2005, 4(1): 55-60.
-
1周本秀,薛迎红,钱立庭,吴韦炜.脑膜癌病的诊治(附7例报告)[J].安徽医学,1995,16(4):31-32.
-
2胡宏年.岩舒注射液治疗Ⅳ期非小细胞肺癌的临床疗效观察[J].肿瘤防治研究,2001,28(5):392-393. 被引量：15
-
3乳腺癌病人术后如何避孕？[J].中国健康月刊,2009(12):53-53.
-
4陈方宏,郑树,余海,谢星辉.脂质体作为甲氨喋呤载体对小鼠大肠肿瘤作用的研究[J].肿瘤,1991,11(4):173-174.
-
5刘继红,陈瑞宝.前列腺癌免疫治疗研究进展[J].中华实验外科杂志,2012,29(12):2355-2356. 被引量：5
-
6颜志坚,朱绍兴.多西紫杉醇治疗激素抵抗型前列腺癌研究进展[J].医学综述,2007,13(3):203-204. 被引量：4
-
7崔晓,冯旭华.激素抵抗型前列腺癌的治疗选择[J].国际肿瘤学杂志,2007,34(12):889-889.
-
8吴翠杰.米非司酮治疗子宫肌瘤70例临床分析[J].中国社区医师（医学专业）,2008,10(8):68-68.
-
9李静辉.米非司酮在子宫肌瘤保守治疗中的应用价值[J].中国实用医药,2009,4(2):131-132. 被引量：19
-
10王春芳.米非司酮治疗子宫肌瘤37例疗效观察[J].临床合理用药杂志,2010,3(19):23-24. 被引量：14
